<DOC>
	<DOCNO>NCT01577160</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness paliperidone ER treatment schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) participant .</brief_summary>
	<brief_title>A Study Evaluate Flexible Dose Paliperidone Extended Release ( ER ) Clinical Response Participants With Schizophrenia</brief_title>
	<detailed_description>This multi-center ( one hospital medical school team work medical research study ) , open-label ( people know identity intervention ) , prospective ( study follow participant forward time ) , non-comparative study . The total study duration 12 week participant include follow visit : Screening , Week 2 , 4 , 8 , 12 ( end treatment early withdrawal ) . The effectiveness paliperidone ER evaluate Week 12 proportion responder evaluate `` much improve '' `` much improve '' Clinical Global Impression improvement ( CGI-I ) Scale . Participants ' safety also monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Participants diagnose schizophrenia ( accord Diagnostic Statistical Manual Mental Disorders [ Edition 4 ] criterion ) Participants Clinical Global ImpressionSeverity ( CGIS ) score great equal 4 point ( moderately ill ) Screening Childbearing potential woman consent consistent use acceptable contraception ( oral contraceptive , contraceptive injection , intrauterine device , double barrier method contraceptive patch ) Participants capable willing fill questionnaire Participants compliant selfmedication receive consistent help support Participants past history neuroleptic malignant syndrome ( high fever , rigid muscle , shake , confusion , sweat usual , increased heart rate blood pressure , muscle pain weakness ) Participants allergy hypersensitivity risperidone paliperidone Participants take clozapine , expose study drug within one month screen Participants treat long act antipsychotic injection within 28 day Participants significant risk include suicide aggressive behavior</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone Extended Release ( ER )</keyword>
</DOC>